1125P - The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Affiliation:
      1 Centre for Health Economics, University of York, York, UK
      2 Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham, UK
      3 SHORE-C/BSMS, University of Sussex, Brighton, UK
      4 Oncology, Brighton&Sussex University Hospitals, Brighton, UK
    • ISSN:
      0923-7534
    • Accession Number:
      10.1093/annonc/mdx375.012
    • Accession Number:
      S0923753420383927
    • Copyright:
      Copyright © 2017 European Society for Medical Oncology Published by Elsevier Ltd on behalf of European Society for Medical Oncology All rights reserved.
  • Citations
    • ABNT:
      HINDE, S. et al. 1125P - The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer. Annals of Oncology, [s. l.], v. 28, n. Supplement 5, p. v399, 2017. DOI 10.1093/annonc/mdx375.012. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edselp&AN=S0923753420383927. Acesso em: 27 nov. 2020.
    • AMA:
      Hinde S, Theriou C, May S, et al. 1125P - The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer. Annals of Oncology. 2017;28(Supplement 5):v399. doi:10.1093/annonc/mdx375.012
    • APA:
      Hinde, S., Theriou, C., May, S., Matthews, L., Arbon, A., Fallowfield, L., & Bloomfield, D. (2017). 1125P - The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer. Annals of Oncology, 28(Supplement 5), v399. https://doi.org/10.1093/annonc/mdx375.012
    • Chicago/Turabian: Author-Date:
      Hinde, S., C. Theriou, S. May, L. Matthews, A. Arbon, L. Fallowfield, and D. Bloomfield. 2017. “1125P - The Cost-Effectiveness of EndoPredict to Inform Adjuvant Chemotherapy Decisions in Early Breast Cancer.” Annals of Oncology 28 (Supplement 5): v399. doi:10.1093/annonc/mdx375.012.
    • Harvard:
      Hinde, S. et al. (2017) ‘1125P - The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer’, Annals of Oncology, 28(Supplement 5), p. v399. doi: 10.1093/annonc/mdx375.012.
    • Harvard: Australian:
      Hinde, S, Theriou, C, May, S, Matthews, L, Arbon, A, Fallowfield, L & Bloomfield, D 2017, ‘1125P - The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer’, Annals of Oncology, vol. 28, no. Supplement 5, p. v399, viewed 27 November 2020, .
    • MLA:
      Hinde, S., et al. “1125P - The Cost-Effectiveness of EndoPredict to Inform Adjuvant Chemotherapy Decisions in Early Breast Cancer.” Annals of Oncology, vol. 28, no. Supplement 5, Sept. 2017, p. v399. EBSCOhost, doi:10.1093/annonc/mdx375.012.
    • Chicago/Turabian: Humanities:
      Hinde, S., C. Theriou, S. May, L. Matthews, A. Arbon, L. Fallowfield, and D. Bloomfield. “1125P - The Cost-Effectiveness of EndoPredict to Inform Adjuvant Chemotherapy Decisions in Early Breast Cancer.” Annals of Oncology 28, no. Supplement 5 (September 1, 2017): v399. doi:10.1093/annonc/mdx375.012.
    • Vancouver/ICMJE:
      Hinde S, Theriou C, May S, Matthews L, Arbon A, Fallowfield L, et al. 1125P - The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer. Annals of Oncology [Internet]. 2017 Sep 1 [cited 2020 Nov 27];28(Supplement 5):v399. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edselp&AN=S0923753420383927